Ms Robertson is the Executive Vice President and Chief Financial Officer of Geron Corporation. Prior to joining Geron Corporation, she served as the Chief Financial Officer of Editas Medicine, a CRISPR genome editing company, where she raised $500M in capital to support the company’s research transition into late-stage clinical development. Before that, she served as Chief Financial Officer of Momenta Pharmaceuticals, from 2018 until 2020, leading the finance team through a strategic restructure, before its acquisition by Johnson & Johnson. Prior to joining Momenta, Ms Robertson held multiple commercial finance roles of increasing responsibility, including Vice President, Oncology Finance for Baxalta following its spin-off from Baxter International where she worked on the acquisition and commercialization of their first oncology drug, Oncaspar and Head of Financial Planning and Analysis and Operations Excellence at Ironwood Pharmaceuticals, positioning the finance organization to support the commercial launch of Linzess. Before that, for 16 years, she held various finance and commercial operations roles at Genzyme Corporation (now Sanofi Genzyme) where she led the integration of several acquired Oncology assets, subsequently leading the buildout of the Commercial operations team to support five global commercial products. Ms Robertson received her B.S. in Finance and A.S. in Accounting and Management from Bentley University.